![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Fcontent%2Fvol8%2Fissue3%2Fimages%2Fmedium%2Ffoc8008f5.gif)
Figure 5. Secondary efficacy outcomes: mean patient-assessed end-of-study effectiveness evaluation (0, poor; 4, excellent) by treatment group. Based on analysis of variance for each of these 3 outcomes, P<.001 for loperamide hydrochloridesimethicone vs each of the other treatment groups.